Recent advances in transmission-blocking drugs for malaria elimination

Future Med Chem. 2019 Dec;11(23):3047-3088. doi: 10.4155/fmc-2019-0225. Epub 2019 Nov 29.

Abstract

The scientific community worldwide has realized that malaria elimination will not be possible without development of safe and effective transmission-blocking interventions. Primaquine, the only WHO recommended transmission-blocking drug, is not extensively utilized because of the toxicity issues in G6PD deficient individuals. Therefore, there is an urgent need to develop novel therapeutic interventions that can target malaria parasites and effectively block transmission. But at first, it is imperative to unravel the existing portfolio of transmission-blocking drugs. This review highlights transmission-blocking potential of current antimalarial drugs and drugs that are in various stages of clinical development. The collective analysis of the relationships between the structure and the activity of transmission-blocking drugs is expected to help in the design of new transmission-blocking antimalarials.

Keywords: Plasmodium falciparum; antimalarials; gametocyte; gametocytocidal; malaria; malaria elimination; sporogonic; sporontocidal; transmission-blocking.

Publication types

  • Review

MeSH terms

  • Antimalarials
  • Disease Eradication
  • Disease Transmission, Infectious / prevention & control*
  • Drug Development / methods*
  • Drug Development / trends
  • Gametogenesis / drug effects
  • Germ Cells / cytology
  • Germ Cells / drug effects
  • Humans
  • Malaria, Falciparum* / drug therapy
  • Malaria, Falciparum* / transmission
  • Parasitic Sensitivity Tests
  • Plasmodium falciparum / drug effects*
  • Plasmodium falciparum / physiology

Substances

  • Antimalarials